Company profile rEVO Biologics, Inc. a subsidiary of LFB Biotechnologies S.A. is a privately held biopharmaceutical company located in the Boston area (Framingham, MA). The company’s mission is to answer the challenges of medicine: how to develop therapies for rare diseases that are accessible within specialized markets. The company’s lead product ATryn®, Antithrombin (Recombinant), is indicated for use in patients with hereditary antithrombin deficiency. The company is exploring additional applications for ATryn including early onset preeclampsia through an ongoing Phase 3 clinical trial in pregnant women called PRESERVE-1 (www.preserve-1.org). Additional information on this clinical trial can be found at www.clinicaltrials.gov. rEVO is always looking for motivated scientific, business and healthcare professionals with an entrepreneurial spirit. For more information about rEVO please visit www.revobiologics.com Company Background rEVO Biologics, Inc. was incorporated in 1993 as a subsidiary of Genzyme Corporation. In 2002, the company changed its name to GTC Biotherapeutics and became a wholly-owned subsidiary of LFB Biotechnologies in 2009. In 2013 the company changed its name to rEVO Biologics.